The frontotemporal disorders treatment market is projected to grow from USD 393.5 million in 2025 to USD 616.9 million by 2035, at a CAGR of 4.6%. Cognitive Enhancers will dominate with a 32.8% market share, while behavioral symptoms management will lead the treatment segment with a 54.6% share.